🔗 Share this article

As America continues making sweeping changes to its vaccine recommendations, a particular individual appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines in the global health crisis and has focused upon alleged fatalities following Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders were set to announce radical changes to the pediatric vaccine schedule recently, bringing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US at odds with much of the international standard with no evidence for benefit. The announcement has been pushed back until the new year.

In place of the director of the vaccine center, Høeg is set to speak at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this calendar year.

Consolidating Power at the Agency

This interim role could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it suggests a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific childhood shot schedules in the US so as to align more similar to Denmark, a society with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

In her initial statements, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Qualifications

The appointee has no obvious track record in pharmaceutical research, regulation or management, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the necessary background” for running the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Previous directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that former directors who headed CBER have had.”

The drug center has an vast workload at the FDA, she emphasized.

“Many people just zeroes in on the novel medication approvals, but the generic program approves a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these have to be supervised,” Dr. Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial management element to the position, which oversees more than 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” the former official said.

Response and Disputed Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among regulatory chiefs on immunizations, a representative said that the “inquiries are based on incorrect presumptions”.

“Her experience aligns with the functions of her position,” the spokesperson stated, pointing to the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg takes over the commissioner’s recently launched priority voucher program, a contentious expedited therapy clearance system that apparently concerned her former heads. “By what process are these drugs being selected for this fast-track system? Who makes the calls?” Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Overall, he said, “the agency appears to be shifting towards laxer regulations of pharmaceuticals, except for immunizations.”

Public History on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, past, some experts said. She released a study using unverified crowd-sourced reports to estimate the frequency of heart inflammation following COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the current federal leadership encompassed changing regulations for recently developed shots and halting “unnecessary” immunizations, she said following the vote on a audio program. At the FDA, Dr. Høeg has allegedly proposed preventing teenage boys from receiving Covid vaccinations.

“She is an all-around ideologue who begins with her conclusions and works backwards to retrofit the data in a very disingenuous, untruthful way,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|